Success Metrics

Clinical Success Rate
83.3%

Based on 10 completed trials

Completion Rate
83%(10/12)
Active Trials
10(32%)
Results Posted
30%(3 trials)
Terminated
2(6%)

Phase Distribution

Ph not_applicable
5
16%
Ph phase_4
1
3%
Ph phase_1
10
32%
Ph phase_2
15
48%

Phase Distribution

10

Early Stage

15

Mid Stage

1

Late Stage

Phase Distribution31 total trials
Phase 1Safety & dosage
10(32.3%)
Phase 2Efficacy & side effects
15(48.4%)
Phase 4Post-market surveillance
1(3.2%)
N/ANon-phased studies
5(16.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

71.4%

10 of 14 finished

Non-Completion Rate

28.6%

4 ended early

Currently Active

10

trials recruiting

Total Trials

31

all time

Status Distribution
Active(10)
Completed(10)
Terminated(4)
Other(7)

Detailed Status

Completed10
Recruiting9
unknown7
Withdrawn2
Terminated2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
31
Active
10
Success Rate
83.3%
Most Advanced
Phase 4

Trials by Phase

Phase 110 (32.3%)
Phase 215 (48.4%)
Phase 41 (3.2%)
N/A5 (16.1%)

Trials by Status

withdrawn26%
unknown723%
active_not_recruiting13%
terminated26%
completed1032%
recruiting929%

Recent Activity

10 active trials
Showing 5 of 31
recruitingphase_2

CBD for Lower Urinary Tract Dysfunction in Spinal Cord Injury

NCT06840899
recruitingphase_2

Cannabis (THC vs. CBD) in Multiple Sclerosis

NCT06261489
recruitingphase_1

Evaluation of Oral THC and CBD in Men and Women

NCT05067387
recruitingphase_1

The Pharmacokinetics of a Hemp-Based Topical Product

NCT07603518
recruitingphase_2

Cannabidiol Medication Intervention Trial

NCT06014424
View all 31 trials

Clinical Trials (31)

Showing 20 of 31 trialsScroll for more
NCT06840899Phase 2

CBD for Lower Urinary Tract Dysfunction in Spinal Cord Injury

Recruiting
NCT06261489Phase 2

Cannabis (THC vs. CBD) in Multiple Sclerosis

Recruiting
NCT05067387Phase 1

Evaluation of Oral THC and CBD in Men and Women

Recruiting
NCT07603518Phase 1

The Pharmacokinetics of a Hemp-Based Topical Product

Recruiting
NCT06014424Phase 2

Cannabidiol Medication Intervention Trial

Recruiting
NCT06878417Not Applicable

Cannabinoids for Osteoarthritis Pain Effectiveness Trial

Recruiting
NCT07656350Not Applicable

Challenging the Endocannabinoid System in Sleep Restricted Healthy Volunteers to Modulate Physiological Arousal (CANISLEEP) Study

Recruiting
NCT05514899Phase 2

Effects of Cannabidiol and Tetrahydrocannabinol on Microbiome and Neuroinflammation in HIV

Recruiting
NCT05066308Phase 2

Cannabidiol for Reduction of Brain Neuroinflammation

Recruiting
NCT04611347Phase 2

Is Topical CBD Effective in Treating Thumb Joint Arthritis

Completed
NCT04286594Phase 2

A Clinical Trial of a Hemp-Derived Cannabidiol Product for Anxiety

Terminated
NCT04283019Phase 1

The Pharmacokinetic and Pharmacodynamic Effects of Oral Cannabidiol (CBD) Under Acute and Chronic Exposure Conditions

Completed
NCT04439955Phase 2

Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol (CBD) as a Steroid-sparing Therapy in Chronic Spontaneous Urticaria (CSU) Patients

Completed
NCT04778644Phase 1

Hippocampal Response to Acute Oral Doses of CBD During an fMRI Memory Task

Active Not Recruiting
NCT03537950Not Applicable

Shifting Brain Excitation-Inhibition Balance in Autism Spectrum Disorder

Completed
NCT05170451Phase 2

Topical CBD for Musculoskeletal Pain

Withdrawn
NCT04741477Phase 1

The Pharmacokinetics and Pharmacodynamics of Hemp-based Topical Cannabinoid Products

Completed
NCT05317013Phase 1

CBD in Postmenopausal Women With Osteopenia

Terminated
NCT02071862Phase 1

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Completed
NCT04768478Phase 4

CBD for Pain Reduction and Opioid Use After Ankle and Tibia Fracture ORIF

Withdrawn

Drug Details

Intervention Type
DRUG
Total Trials
31